Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
Finished Drug Prices
NA
1. 2-(alpha-(2,6-dichlorophenoxy)ethyl) Delta-2-imidazoline
2. Britlofex
3. Lofexidine
4. Lofexidine Mono-hydrochloride
5. Lofexidine Monohydrochloride
6. Lofexidine, (+-)-isomer
7. Lucemyra
1. 21498-08-8
2. Lofexidine Hcl
3. Lofexidine.hcl
4. Lofexidine (hydrochloride)
5. Britlofex
6. Mdl 14,042
7. Lofexidine Hydrochloride [usan]
8. Mdl-14042
9. Nsc-759654
10. V47g1sdi1b
11. 2-(1-(2,6-dichlorophenoxy)ethyl)-4,5-dihydro-1h-imidazole Hydrochloride
12. 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1h-imidazole;hydrochloride
13. Lucemyra
14. Lofetensin
15. Loxacor
16. Baq-168;mdl-14042
17. 2-(1-(2,6-dichlorophenoxy)ethyl)-2-imidazoline Monohydrochloride
18. 1h-imidazole, 2-(1-(2,6-dichlorophenoxy)ethyl)-4,5-dihydro-, Monohydrochloride
19. Lofexidine Hydrochloride (usan)
20. 2-(1-(2,6-dichlorophenoxy)ethyl)-2-imidazoline Hydrochloride
21. 2-[1-(2,6-dichlorophenoxy)ethyl]-2-imidazoline Hydrochloride
22. Loxacor Hydrochloride
23. Lofetensin Hydrochloride
24. Lofexidine Hcl
25. Lofexidine (tn)
26. Rmi-14042a
27. Lucemyra (tn)
28. Ba 168
29. Mfcd00917022
30. Unii-v47g1sdi1b
31. Mls001424245
32. Schembl124601
33. Chembl1788132
34. Dtxsid0020781
35. Pharmakon1600-01502357
36. Bcp30600
37. Hy-b1052
38. 2-(1-(2,6-dichlorphenoxy)aethyl)-2-imidazolin-hydrochlorid [german]
39. Lofexidine Hydrochloride [mi]
40. Nsc759654
41. Zb0287
42. 2-{1-[(2,6-dichlorophenyl)oxy]ethyl}-4,5-dihydro-1h-imidazole Hydrochloride
43. 2-imidazoline, 2-(1-(2,6-dichlorophenoxy)ethyl)-, Monohydrochloride
44. Akos015902903
45. Ccg-101139
46. Ccg-213049
47. Cs-4574
48. Nc00389
49. Nsc 759654
50. (-)-2-[1-(2,6-dichlorophenoxy)-ethyl]-1,3-diazacyclopent-2-ene Hydrochloride
51. Lofexidine Hydrochloride [mart.]
52. Lofexidine Hydrochloride [vandf]
53. Lofexidine Hydrochloride [who-dd]
54. As-31095
55. Smr000469232
56. Ft-0651655
57. Ft-0670833
58. Sw197769-3
59. Lofexidine Hydrochloride [orange Book]
60. D04765
61. 498l088
62. A815419
63. J-014106
64. Q27291521
65. 2-(1-(2,6-dichlorphenoxy)aethyl)-2-imidazolin-hydrochlorid
66. 2-[1-(2,6-dichlorophenoxy) -ethyl]2-imidazoline Hydrochloride
67. 2-(1-(2,6-dichlorophenoxy)ethyl)-4,5-dihydro-1h-imidazolehydrochloride
68. Lofexidine Hcl;lofexidine Monohydrochloride;baq-168; Mdl-14042;ba 168;mdl 14,042
Molecular Weight | 295.6 g/mol |
---|---|
Molecular Formula | C11H13Cl3N2O |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 3 |
Exact Mass | 294.009346 g/mol |
Monoisotopic Mass | 294.009346 g/mol |
Topological Polar Surface Area | 33.6 Ų |
Heavy Atom Count | 17 |
Formal Charge | 0 |
Complexity | 263 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Narcotic Antagonists
Agents inhibiting the effect of narcotics on the central nervous system. (See all compounds classified as Narcotic Antagonists.)
Adrenergic alpha-2 Receptor Agonists
Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS. (See all compounds classified as Adrenergic alpha-2 Receptor Agonists.)
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
Medichem is a vertically integrated pharmaceutical company specializing in the development & manufacturing of APIs & FDFs.
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-08-15
Pay. Date : 2023-07-17
DMF Number : 37978
Submission : 2023-07-17
Status : Active
Type : II
NDC Package Code : 16436-0128
Start Marketing Date : 2020-11-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (75kg/75kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-01-23
Pay. Date : 2022-12-13
DMF Number : 37543
Submission : 2022-10-25
Status : Active
Type : II
NDC Package Code : 46016-2140
Start Marketing Date : 2020-04-09
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-01-30
Pay. Date : 2023-01-23
DMF Number : 34636
Submission : 2020-02-28
Status : Active
Type : II
Date of Issue : 2022-06-17
Valid Till : 2025-07-14
Written Confirmation Number : WC-0021n
Address of the Firm :
NDC Package Code : 14501-0098
Start Marketing Date : 2020-02-27
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Date of Issue : 2022-01-04
Valid Till : 2022-07-14
Written Confirmation Number : WC-0021A4
Address of the Firm :
NDC Package Code : 14501-0098
Start Marketing Date : 2020-02-27
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Lofexidine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lofexidine, including repackagers and relabelers. The FDA regulates Lofexidine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lofexidine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Lofexidine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Lofexidine supplier is an individual or a company that provides Lofexidine active pharmaceutical ingredient (API) or Lofexidine finished formulations upon request. The Lofexidine suppliers may include Lofexidine API manufacturers, exporters, distributors and traders.
click here to find a list of Lofexidine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Lofexidine DMF (Drug Master File) is a document detailing the whole manufacturing process of Lofexidine active pharmaceutical ingredient (API) in detail. Different forms of Lofexidine DMFs exist exist since differing nations have different regulations, such as Lofexidine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Lofexidine DMF submitted to regulatory agencies in the US is known as a USDMF. Lofexidine USDMF includes data on Lofexidine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Lofexidine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Lofexidine suppliers with USDMF on PharmaCompass.
A Lofexidine written confirmation (Lofexidine WC) is an official document issued by a regulatory agency to a Lofexidine manufacturer, verifying that the manufacturing facility of a Lofexidine active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Lofexidine APIs or Lofexidine finished pharmaceutical products to another nation, regulatory agencies frequently require a Lofexidine WC (written confirmation) as part of the regulatory process.
click here to find a list of Lofexidine suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Lofexidine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Lofexidine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Lofexidine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Lofexidine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Lofexidine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Lofexidine suppliers with NDC on PharmaCompass.
Lofexidine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lofexidine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lofexidine GMP manufacturer or Lofexidine GMP API supplier for your needs.
A Lofexidine CoA (Certificate of Analysis) is a formal document that attests to Lofexidine's compliance with Lofexidine specifications and serves as a tool for batch-level quality control.
Lofexidine CoA mostly includes findings from lab analyses of a specific batch. For each Lofexidine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lofexidine may be tested according to a variety of international standards, such as European Pharmacopoeia (Lofexidine EP), Lofexidine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lofexidine USP).
LOOKING FOR A SUPPLIER?